Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Prioritized Flu Vaccinations for Elderly from October 1, Others Asked to Wait until October 26
The Ministry of Health, Labor and Welfare (MHLW) on September 11 issued a notification to prefectural health authorities, calling for prioritized flu vaccinations for the elderly aged 65 or above from October 1, with others asked to wait until October…
To read the full story
Related Article
- Priority Shots for Seasonal Flu Begin for Elderly, Other High-Risk People
October 1, 2020
- MHLW Calls for Smooth Supply of Flu Shots as It Anticipates Surging Demand
September 11, 2020
- MHLW Panels Agree to Prioritize Flu Vaccinations for Elderly, and Then HCPs
August 27, 2020
- MHLW Likely to Secure Largest Volume of Flu Vaccines since Quadrivalent Switch: Kato
August 26, 2020
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…